Transcranial Magnetic Stimulation for Treatment of Methamphetamine Dependence

Not Applicable

Completed

• Conditions: Methamphetamine-dependence
• Interventions: Device: rTMS treatment group; Device: sham rTMS treatment group

• Registration Number: NCT03827785
• Lead Sponsor: Shanghai Mental Health Center

Brief Summary

Repetitive transcranial magnetic stimulation (rTMS) was used to treat methamphetamine (MA) addiction in previous studies, while the evidence-based protocols still required. The aim of this research is to evaluating the effectiveness and safety of rTMS treatment in improving the days of abstinence maintenance. In addition, treatment effect on cognitive impairment, psychological craving and depression are also evaluated during the study.

Detailed Description

First, a multicenter, double-blind, randomized control study is going to be carried out. 100 recruited patients will be randomized assigned to the intervention group and the control group, receiving either 4-week of repetitive transcranial magnetic stimulation (rTMS) treatment or 4-week of sham rTMS treatment. Both groups will receive 12-week urine drug test follow-up (1 time per week). Negative rate of urine test during the follow-up period is set as primary outcome. Cognitive function, craving, depression are also evaluated before and after the intervention.

Secondly, another 40 patients will be recruited from these 100 patients (20 subjects each group). Magnetic resonance spectroscopy (MRS) test is applied to investigate the potential neurobiological mechanism of rTMS treatment. This study will be very helpful to develop an evidence-based rTMS treatment protocols for MA dependent patients and decrease risk of relapse for both the patients and their families.

Study Timeline

• Study First Submitted: 2019-01-30
• Study First Submitted QC: 2019-01-30
• Study Start: 2019-02-01
• Study First Posted: 2019-02-01
• Primary Completion: 2020-09-01
• Study Completion: 2020-12-12
• Status Verified: 2021-09
• Last Update Submitted: 2021-09-13
• Last Update Posted: 2021-09-16

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 100

Inclusion Criteria

1. In accordance with the Diagnostic and Statistical Manual of Mental Disorders-5 (DSM-5) for methamphetamine (MA) use disorders
2. Junior high school degree or above
3. Normal vision and hearing
4. Dextromanual
5. Less than one month before last drug use

Exclusion Criteria

1. Have a disease that affect cognitive function such as history of head injury, cerebrovascular disease, epilepsy, etc
2. Have cognitive-promoting drugs in the last 6 months
3. Other substance abuse or dependence in recent five years (except nicotine)
4. Mental impairment, Intelligence Quotient (IQ) < 70
5. Mental disorders
6. Physical disease

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
rTMS treatment group	rTMS treatment group	Stimulate the dorsal lateral prefrontal cortex with the iTBS pattern. The therapy will be conducted for 30 days.
sham rTMS treatment group	sham rTMS treatment group	Stimulate the dorsal lateral prefrontal cortex with the sham iTBS pattern and coil. The therapy will be conductedfor 30 days.

Primary Outcome Measures

Name	Time	Method
Negative rate urine test	12 weeks	After treatment, patients will be asked to participate urine test for 12 times once a week. Loss of visit or rejection for urine test will be treated as urine test positive.; Negative rate of urine drug test = actual number of negative urine tests / 12.

Secondary Outcome Measures

Name	Time	Method
Cognitive function assessed by CogState Battery (CSB)	12 weeks	evaluate all participants' cognitive function by the computerized CogState Battery (CSB) Chinese version
Change of Craving assessed by Visual Analog Scale	12 weeks	evaluate all participants' craving for for methamphetamine assessed by Visual Analog Scales (VAS). Score of VAS range from 0 to 10, and higher values represent high level of craving.
Depression status assessed by Hamilton depression scale (HAMD-17)	12 weeks	Evaluate all participants' depression status by Hamilton depression scale (HAMD-17) HAMD can be summarized into 7 types of factor structure: (1) anxiety/somatization:; (2) weight: weight loss (3) Cognitive obstacles; (4) day and night changes; (5) Block; (6) sleep disorder; (7) feeling of despair. The total score can reflect the severity of the symptom, that is, The lighter the symptoms, the lower the score, and vice versa. Mild depression: HAMD 17 scores \> 7 points, ≤ 17 points; moderate depression: HAMD 17 scores \> 17 points, ≤ 24 points; severe depression: HAMD 17 scores \> 24 points.

Trial Locations

Locations (1)

Shanghai Rehabilitation Center; 🇨🇳 Shanghai, China